RCKT Stock Price, Rocket Pharmaceuticals Quote, Chart

Market Summary

USD23.63-0.04

Delayed

-0.17%

RCKT Alerts

3 major insider sales recently.

RCKT Stock Price

View Fullscreen

RCKT RSI Chart

RCKT Valuation

Market Cap

2.1B

Price/Earnings (Trailing)

-8.71

Price/Sales (Trailing)

404.43

Price/Free Cashflow

-10.12

RCKT Price/Sales (Trailing)

RCKT Profitability

Return on Equity

-49.86%

Return on Assets

-43.37%

Free Cashflow Yield

-9.88%

RCKT Fundamentals

RCKT Revenue

Revenue (TTM)

5.3M

Rev. Growth (Yr)

-34.59%

Rev. Growth (Qtr)

-52.67%

RCKT Earnings

Earnings (TTM)

-245.6M

Earnings Growth (Yr)

10.59%

Earnings Growth (Qtr)

3.62%

Breaking Down RCKT Revenue

Last 7 days

-0.2%

Last 30 days

-12.2%

Last 90 days

-16.9%

Trailing 12 Months

33.0%

How does RCKT drawdown profile look like?

RCKT Financial Health

Current Ratio

7.8

RCKT Investor Care

Shares Dilution (1Y)

14.06%

Diluted EPS (TTM)

-2.92

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	5.2M	5.4M	5.7M	5.3M
2022	2.8M	2.9M	3.5M	3.9M
2021	2.1M	2.2M	2.5M	3.1M
2020	3.8M	3.2M	2.8M	2.2M
2019	2.0M	2.5M	3.1M	3.4M
2018	0	0	0	1.7M
2017	0	0	0	0
2016	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Rocket Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 22, 2024	militello john	sold	-19,050	22.87	-833	see remarks
Apr 15, 2024	southwell david p	acquired	128,627	4.342	29,624	-
Apr 15, 2024	southwell david p	sold	-240,520	24.052	-10,000	-
Apr 12, 2024	southwell david p	acquired	303,940	4.342	70,000	-
Apr 12, 2024	southwell david p	sold	-1,705,260	24.3609	-70,000	-
Apr 08, 2024	white mark andrew	sold	-308,763	24.638	-12,532	see remarks
Apr 01, 2024	ondrey aaron	acquired	-	-	46,781	chief financial officer
Mar 21, 2024	makker gotham	sold	-7,790,940	28.4341	-274,000	-
Mar 21, 2024	militello john	sold	-69,979	28.104	-2,490	see remarks
Feb 29, 2024	militello john	acquired	125,500	12.55	10,000	see remarks

Which funds bought or sold RCKT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-75.27	-201,000	58,000	-%
Apr 23, 2024	Global Retirement Partners, LLC	sold off	-100	-5,704	-	-%
Apr 23, 2024	RICE HALL JAMES & ASSOCIATES, LLC	added	0.14	-216,763	1,953,900	0.11%
Apr 23, 2024	Gradient Investments LLC	sold off	-100	-1,019	-	-%
Apr 22, 2024	EFG Asset Management (Americas) Corp.	reduced	-37.35	-156,751	202,050	0.06%
Apr 22, 2024	MetLife Investment Management, LLC	added	14.17	396,816	989,100	0.01%
Apr 17, 2024	Hennion & Walsh Asset Management, Inc.	added	19.62	436,172	6,230,870	0.33%
Apr 16, 2024	Harbour Capital Advisors, LLC	added	115	261,706	543,684	0.14%
Apr 15, 2024	Legato Capital Management LLC	new	-	300,623	300,623	0.04%
Apr 11, 2024	SANDERS MORRIS HARRIS LLC	unchanged	-	-67,334	746,480	0.14%

Are Funds Buying or Selling RCKT?

Are funds buying RCKT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RCKT

No. of Funds

RCKT Alerts

3 major insider sales recently.

Unveiling Rocket Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	wellington management group llp	10.12%	9,156,099	SC 13G/A
Feb 13, 2024	vanguard group inc	6.04%	5,447,565	SC 13G/A
Feb 08, 2024	wellington management group llp	9.09%	8,197,546	SC 13G
Jan 29, 2024	blackrock inc.	6.6%	5,930,178	SC 13G/A
Jan 22, 2024	state street corp	3.58%	3,231,411	SC 13G/A
Sep 19, 2023	rtw investments, lp	20.21%	18,188,457	SC 13D/A
Apr 05, 2023	rtw investments, lp	22.9%	18,188,457	SC 13D/A
Feb 09, 2023	vanguard group inc	5.32%	4,186,542	SC 13G/A
Feb 06, 2023	wellington management group llp	4.45%	3,507,017	SC 13G/A
Jan 31, 2023	state street corp	5.05%	3,978,985	SC 13G

Recent SEC filings of Rocket Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 24, 2024	4	Insider Trading
Apr 22, 2024	144	Notice of Insider Sale Intent
Apr 17, 2024	PRE 14A	PRE 14A
Apr 16, 2024	4	Insider Trading
Apr 15, 2024	144	Notice of Insider Sale Intent
Apr 12, 2024	144	Notice of Insider Sale Intent
Apr 10, 2024	4	Insider Trading
Apr 08, 2024	144	Notice of Insider Sale Intent
Apr 05, 2024	SC 13G/A	Major Ownership Report
Apr 03, 2024	3	Insider Trading

Peers (Alternatives to Rocket Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Rocket Pharmaceuticals Inc News

Latest updates

Rocket Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-52.7%	814	1,720	846	1,908	1,245	1,353	669	623	850	806	501	911	237	518	429	967	863	979	1,000	601	484
Operating Expenses	-3.3%	63,279	65,429	68,757	62,194	69,082	58,488	54,210	42,564	44,333	49,646	34,048	39,222	59,237	27,387	23,559	24,120	19,649	19,165	18,392	18,945	26,546
S&GA Expenses	15.9%	21,535	18,585	17,374	15,823	19,045	15,105	12,854	11,770	11,316	10,025	9,518	10,913	9,145	5,730	6,828	7,163	5,697	4,336	4,403	3,808	2,861
R&D Expenses	-10.9%	41,744	46,844	51,383	46,371	50,037	43,383	41,356	30,794	33,017	39,621	24,530	28,309	50,093	21,657	16,731	16,957	13,952	14,829	13,989	15,137	23,685
Interest Expenses	0.2%	470	469	468	468	468	465	465	464	463	534	251	1,729	1,641	1,967	1,786	1,573	1,344	1,466	1,544	1,604	2,051
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26.00	-	-	-	-
Net Income	3.6%	-59,660	-61,899	-65,701	-58,335	-66,723	-57,756	-54,402	-42,982	-44,247	-50,118	-34,525	-40,179	-60,916	-29,080	-25,040	-24,664	-19,855	-19,284	-18,680	-19,451	-27,319
Net Income Margin	-5.1%	-46.44*	-44.18*	-46.44*	-45.84*	-57.04*	-57.05*	-65.04*	-61.82*	-55.11*	-75.67*	-76.02*	-74.11*	-	-	-	-	-	-	-	-	-
Free Cashflow	45.0%	-33,986	-61,803	-54,988	-60,575	-59,024	-44,362	-41,936	-41,178	-32,906	-31,294	-39,972	-24,611	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-5.4%	566	599	462	515	552	417	432	460	497	530	535	576	591	335	353	373	372	300	309	242	251
Current Assets	-15.4%	378	447	312	338	364	311	326	354	392	425	430	472	487	233	255	280	308	246	264	200	209
Cash Equivalents	-75.2%	56.00	226	45.00	65.00	141	198	189	132	234	247	266	254	299	84.00	165	192	187	91.00	66.00	126	113
Net PPE	7.2%	39.00	37.00	33.00	31.00	29.00	26.00	25.00	24.00	22.00	22.00	21.00	20.00	19.00	16.00	14.00	11.00	30.00	19.00	10.00	7.00	2.00
Goodwill	0%	39.00	39.00	39.00	39.00	39.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00
Liabilities	27.9%	74.00	58.00	59.00	56.00	62.00	50.00	44.00	43.00	42.00	45.00	46.00	96.00	87.00	94.00	87.00	87.00	65.00	68.00	60.00	65.00	57.00
Current Liabilities	44.9%	49.00	33.00	34.00	31.00	39.00	30.00	24.00	23.00	22.00	24.00	25.00	40.00	33.00	32.00	21.00	21.00	18.00	22.00	15.00	21.00	15.00
Shareholder's Equity	-9.0%	493	541	403	459	490	367	388	418	455	486	489	480	504	242	267	286	307	232	249	177	194
Retained Earnings	-6.6%	-959	-899	-837	-772	-713	-647	-589	-534	-491	-447	-397	-363	-322	-261	-232	-207	-183	-163	-144	-125	-105
Additional Paid-In Capital	0.7%	1,451	1,440	1,241	1,230	1,203	1,014	977	952	946	933	886	842	826	503	499	494	490	395	392	302	300
Shares Outstanding	0.2%	90.00	90.00	81.00	80.00	79.00	66.00	65.00	65.00	63.00	63.00	62.00	62.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	1,200	-	-	-	644	-	-	-	1,900	-	-	-	735	-	-	-	463	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	48.7%	-29,339	-57,148	-50,869	-57,560	-56,021	-43,859	-39,039	-39,223	-30,941	-27,413	-38,526	-24,283	-13,109	-17,253	-22,033	-22,245	-19,733	-10,849	-18,104	-15,977	-20,814
Share Based Compensation	-3.7%	9,930	10,316	10,245	8,915	9,693	7,677	7,369	6,270	7,037	6,989	7,311	7,900	6,070	4,047	4,489	3,961	3,359	2,693	4,139	3,180	2,821
Cashflow From Investing	-391.8%	-140,805	48,254	31,206	-36,721	-108,585	23,465	78,789	-62,995	16,864	-18,189	49,352	-29,174	-54,462	-64,193	-5,435	27,499	23,514	35,180	-126,880	29,175	19,049
Cashflow From Financing	-99.8%	391	189,485	182	18,343	108,440	29,526	17,246	76.00	1,136	26,638	1,115	8,792	282,443	512	151	-117	92,407	31.00	85,353	-	74,835
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	72.00	-727	-	-	727	-

RCKT Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Consolidated Statements of Operations [Abstract]
Revenue	$ 0	$ 0	$ 0
Operating expenses:
Research and development	186,342	165,570	125,476
General and administrative	73,317	58,773	41,772
Total operating expenses	259,659	224,343	167,248
Loss from operations	(259,659)	(224,343)	(167,248)
Research and development incentives		500	1,000
Interest expense	(1,875)	(1,862)	(2,977)
Interest and other income, net	5,288	3,889	3,068
Accretion of discount and amortization of premium on investments, net	10,651	(47)	(2,912)
Net loss	$ (245,595)	$ (221,863)	$ (169,069)
Net loss per share attributable to common stockholders - basic (in dollars per share)	$ (2.92)	$ (3.26)	$ (2.67)
Net loss per share attributable to common stockholders - diluted (in dollars per share)	$ (2.92)	$ (3.26)	$ (2.67)
Weighted-average common shares outstanding - basic (in shares)	84,009,004	68,148,925	63,235,417
Weighted-average common shares outstanding - diluted (in shares)	84,009,004	68,148,925	63,235,417

RCKT Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 55,904	$ 140,517
Investments	317,271	215,877
Prepaid expenses and other current assets	5,047	7,666
Total current assets	378,222	364,060
Property and equipment, net	39,172	29,009
Goodwill	39,154	39,154
Intangible assets	25,150	25,724
Restricted cash	1,372	1,340
Deposits	533	608
Investments	34,320	43,276
Operating lease right-of-use assets, net	3,901	1,972
Finance lease right-of-use asset, net	44,517	46,664
Total assets	566,341	551,807
Current liabilities:
Accounts payable and accrued expenses	45,789	36,660
Operating lease liabilities, current	925	773
Finance lease liability, current	1,791	1,736
Total current liabilities	48,505	39,169
Operating lease liabilities, non-current	2,973	1,088
Finance lease liability, non-current	19,353	19,269
Other liabilities	2,936	2,595
Total liabilities	73,767	62,121
Commitments and contingencies (Note 14)
Stockholders' equity:
Common stock, $0.01 par value, 120,000,000 shares authorized; 90,282,267 and 79,123,312 shares issued and 90,282,267 and 79,120,741 shares outstanding at December 31, 2023 and December 31, 2022, respectively	903	791
Treasury stock, at cost, 0 common shares at December 31, 2023 and 2,571 common shares at December 31, 2022	0	(47)
Additional paid-in capital	1,450,722	1,203,074
Accumulated other comprehensive income (loss)	319	(357)
Accumulated deficit	(959,370)	(713,775)
Total stockholders' equity	492,574	489,686
Total liabilities and stockholders' equity	566,341	551,807
Series A Convertible Preferred Shares
Stockholders' equity:
Preferred stock
Series B Convertible Preferred Shares
Stockholders' equity:
Preferred stock

About Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones EnergÃƒÂ©ticas, Medioambientales y TecnolÃƒÂ³gicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. The company is headquartered in Cranbury, New Jersey.

CEO	Dr. Gaurav D. Shah M.D.
WEBSITE	https://rocketpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	240

Rocket Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Rocket Pharmaceuticals Inc? What does RCKT stand for in stocks?

RCKT is the stock ticker symbol of Rocket Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Rocket Pharmaceuticals Inc (RCKT)?

As of Wed Apr 24 2024, market cap of Rocket Pharmaceuticals Inc is 2.14 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RCKT stock?

You can check RCKT's fair value in chart for subscribers.

What is the fair value of RCKT stock?

You can check RCKT's fair value in chart for subscribers. The fair value of Rocket Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Rocket Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RCKT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Rocket Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether RCKT is over valued or under valued. Whether Rocket Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Rocket Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RCKT.

What is Rocket Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, RCKT's PE ratio (Price to Earnings) is -8.71 and Price to Sales (PS) ratio is 404.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RCKT PE ratio will change depending on the future growth rate expectations of investors.